Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial

IMPORTANCE: Clinical outcomes for glioblastoma remain poor. Treatment with immune checkpoint blockade has shown benefits in many cancer types. To our knowledge, data from a randomized phase 3 clinical trial evaluating a programmed death-1 (PD-1) inhibitor therapy for glioblastoma have not been repor...

Full description

Saved in:
Bibliographic Details
Published in:JAMA Oncol
Main Authors: Reardon, David A., Brandes, Alba A., Omuro, Antonio, Mulholland, Paul, Lim, Michael, Wick, Antje, Baehring, Joachim, Ahluwalia, Manmeet S., Roth, Patrick, Bähr, Oliver, Phuphanich, Surasak, Sepulveda, Juan Manuel, De Souza, Paul, Sahebjam, Solmaz, Carleton, Michael, Tatsuoka, Kay, Taitt, Corina, Zwirtes, Ricardo, Sampson, John, Weller, Michael
Format: Artigo
Language:Inglês
Published: American Medical Association 2020
Subjects:
Original Investigation
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7243167/
https://ncbi.nlm.nih.gov/pubmed/32437507
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2020.1024
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items